



## Living Cell Technologies Limited Company Announcement

### Appendix 4C Quarterly Cash Flow Report 30 June 2012

**23 July 2012: Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY)**, announced today the quarterly cash flow report for the quarter ended 30 June 2012. The Appendix 4C is attached. The cash balance at the end of the quarter was \$3,170,000 compared to \$2,662,000 at 31 March 2012. This increase reflects the net proceeds from the Share Purchase Plan of \$1,013,000 and the services fee received from Diatranz Otsuka Limited (DOL) for the continuing development cost of DIABECELL<sup>®</sup>, partially offset by the cost of developing NTCELL for the treatment of Parkinson's disease.

Net operating cash flow in the quarter was (\$491,000) compared to \$95,000 last quarter. Receipts from customers were \$1,529,000 reflecting the services provided to DOL (last quarter \$1,868,000). Operating payments were \$2,040,000 compared to \$1,962,000 last quarter. They include payments for the services provided to DOL for the development of DIABECELL, costs of the NTCELL clinical trial application and continuing preparation for the Good Manufacturing Practice manufacture of NTCELL for the clinical trial in the first quarter of 2013.

Capital expenditure was \$2,000 in the quarter, compared to \$0 last quarter as DOL is investing in fixed assets.

- Ends -

For further information: [www.lctglobal.com](http://www.lctglobal.com)

|  |   |
|--|---|
| <p><b>At the company:</b><br/>Dr Andrea Grant, Chief Executive<br/>Tel: +64 9 270 7941<br/>Mobile: +64 21 078 5421<br/><a href="mailto:agrants@lctglobal.com">agrants@lctglobal.com</a></p> <p>John Cowan, Head of Finance &amp; Administration<br/>Tel: +64 9 276 2690<br/>Mobile: +64 21 469000<br/><a href="mailto:jcowan@lctglobal.com">jcowan@lctglobal.com</a></p> | <p><b>Media enquiries:</b><br/>Sally Raudon<br/>Botica Butler Raudon Partners<br/>Tel: +64 9 303 3862<br/>Mobile: +64 21 402 502<br/><a href="mailto:sallyr@botica.co.nz">sallyr@botica.co.nz</a></p> |
|--|---|

### About Living Cell Technologies

Living Cell Technologies (LCT) leads the world in developing cell-based therapeutics to treat diseases with high unmet clinical need. Its proprietary cell encapsulation technology IMMUPEL<sup>™</sup> allows for cell transplantation without the need for immunosuppressant drugs.

LCT's lead therapeutic candidate DIABECELL<sup>®</sup> is indicated for the treatment of patients with type 1 diabetes, especially those suffering from life threatening episodes of unaware

hypoglycaemia (low blood sugar), a dangerous and potentially fatal diabetes complication. DIABECCELL is currently in Phase II clinical trials in both New Zealand and Argentina.

In 2011, LCT formed a partnership with Otsuka Pharmaceutical Factory Inc (OPF) in which the joint venture Diatranz Otsuka Limited (NZ) was established. Valued at A\$50m on formation, LCT vested the DIABECCELL product and associated IP into the JV, while OPF vested A\$25m to fund the final phase of development of DIABECCELL through to market approval. Both LCT and OPF are 50:50 shareholders in the current and future value generated by DIABECCELL and the associated IP.

LCT has also developed NTCELL, a choroid plexus cell product, to treat neurodegenerative diseases such as Parkinson's disease and stroke. NTCELL's trial results indicate potential for protecting, repairing and possibly regenerating brain tissue which would otherwise die.

LCT is incorporated in Australia. Research and development, operations and manufacturing facilities are based in New Zealand.

### **LCT Disclaimer**

*This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential", "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.*